In the first quarter of 2025, Hau Giang Pharmaceutical Joint Stock Company (DHG) reported noteworthy business results. Compared to the same period last year, DHG’s revenue grew significantly, reaching 1.5 trillion VND, equivalent to a growth rate of 15%. Net profit also showed considerable improvement, reaching 300 billion VND, a 20% increase from Q1/2024.
The increase in revenue and profit mainly stemmed from market expansion and enhancements in core products, alongside effective marketing strategies. The company focused on improving product quality and expanding its range of medications to meet the growing market demand.
Additionally, DHG has intensified its exports to international markets, which has contributed to rising revenues from overseas operations. Despite facing challenges due to the economic situation and competition in the pharmaceutical sector, DHG is confident in its ability to maintain growth momentum moving forward.
Leave a Reply